Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals
Copyright © 2023. Published by Elsevier B.V..
BACKGROUND: We aimed at evaluating the temporal trend of drug-resistance and APOBEC editing from HIV-DNA genotypic resistance tests (GRT) in virologically suppressed individuals.
MATERIAL AND METHODS: Major resistance mutations (MRM), genotypic susceptibility score (GSS) for the current regimen and APOBEC-related mutations (APO-M) were evaluated. Potential changes in trends of MRM and APO-M over-time were assessed and predictors of MRM detection or sub-optimal GSS (GSS<2) at HIV-DNA-GRT were estimated through logistic regression analyses.
RESULTS: Among the 1126 individuals included, 396 (35.2%) harboured at least one MRM (23.4% to NRTI, 18.8% to NNRTI, 7.7% to PI and 1.4% to INSTI [N=724]); 132 (12.3%) individuals showed a GSS <2. APO-M and stop codons were found in 229 (20.3%) and 105 (9.3%) individuals, respectively. APO-DRMs were found in 16.8% of individuals and were more likely observed in those individuals with stop codons (40.0%) compared to those without (14.4%, P<0.001). From 2010 to 2021 no significant changes of resistance or APO-M were found. Positive predictors of MRM detection at HIV-DNA GRT were drug abuse, subtype B infection, and a prolonged and complex treatment history. Perinatal infection and having at least 2 stop codons were associated with a current suboptimal regimen.
CONCLUSIONS: In virologically suppressed individuals, resistance in HIV-DNA and the extent of APOBEC editing were generally stable in the last decade. A careful evaluation of APOBEC editing might be helpful to improve the reliability of HIV-DNA GRT. Further investigations are required to understand how to apply the estimation of APOBEC editing in refining genotypic evaluation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:168 |
|---|---|
| Enthalten in: |
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 168(2023) vom: 07. Nov., Seite 105551 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Armenia, D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
APOBEC editing |
|---|
| Anmerkungen: |
Date Revised 12.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.jcv.2023.105551 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360726607 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360726607 | ||
| 003 | DE-627 | ||
| 005 | 20231226083627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcv.2023.105551 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM360726607 | ||
| 035 | |a (NLM)37573167 | ||
| 035 | |a (PII)S1386-6532(23)00174-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Armenia, D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: We aimed at evaluating the temporal trend of drug-resistance and APOBEC editing from HIV-DNA genotypic resistance tests (GRT) in virologically suppressed individuals | ||
| 520 | |a MATERIAL AND METHODS: Major resistance mutations (MRM), genotypic susceptibility score (GSS) for the current regimen and APOBEC-related mutations (APO-M) were evaluated. Potential changes in trends of MRM and APO-M over-time were assessed and predictors of MRM detection or sub-optimal GSS (GSS<2) at HIV-DNA-GRT were estimated through logistic regression analyses | ||
| 520 | |a RESULTS: Among the 1126 individuals included, 396 (35.2%) harboured at least one MRM (23.4% to NRTI, 18.8% to NNRTI, 7.7% to PI and 1.4% to INSTI [N=724]); 132 (12.3%) individuals showed a GSS <2. APO-M and stop codons were found in 229 (20.3%) and 105 (9.3%) individuals, respectively. APO-DRMs were found in 16.8% of individuals and were more likely observed in those individuals with stop codons (40.0%) compared to those without (14.4%, P<0.001). From 2010 to 2021 no significant changes of resistance or APO-M were found. Positive predictors of MRM detection at HIV-DNA GRT were drug abuse, subtype B infection, and a prolonged and complex treatment history. Perinatal infection and having at least 2 stop codons were associated with a current suboptimal regimen | ||
| 520 | |a CONCLUSIONS: In virologically suppressed individuals, resistance in HIV-DNA and the extent of APOBEC editing were generally stable in the last decade. A careful evaluation of APOBEC editing might be helpful to improve the reliability of HIV-DNA GRT. Further investigations are required to understand how to apply the estimation of APOBEC editing in refining genotypic evaluation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a APOBEC editing | |
| 650 | 4 | |a Drug-resistance | |
| 650 | 4 | |a Genotypic susceptibility score | |
| 650 | 4 | |a HIV-DNA GRT | |
| 650 | 4 | |a PBMCs | |
| 650 | 4 | |a Virological suppression | |
| 700 | 1 | |a Gagliardini, R |e verfasserin |4 aut | |
| 700 | 1 | |a Alteri, C |e verfasserin |4 aut | |
| 700 | 1 | |a Svicher, V |e verfasserin |4 aut | |
| 700 | 1 | |a Cento, V |e verfasserin |4 aut | |
| 700 | 1 | |a Borghi, V |e verfasserin |4 aut | |
| 700 | 1 | |a Vergori, A |e verfasserin |4 aut | |
| 700 | 1 | |a Cicalini, S |e verfasserin |4 aut | |
| 700 | 1 | |a Forbici, F |e verfasserin |4 aut | |
| 700 | 1 | |a Fabeni, L |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoli, A |e verfasserin |4 aut | |
| 700 | 1 | |a Brugneti, M |e verfasserin |4 aut | |
| 700 | 1 | |a Gennari, W |e verfasserin |4 aut | |
| 700 | 1 | |a Malagnino, V |e verfasserin |4 aut | |
| 700 | 1 | |a Andreoni, M |e verfasserin |4 aut | |
| 700 | 1 | |a Mussini, C |e verfasserin |4 aut | |
| 700 | 1 | |a Antinori, A |e verfasserin |4 aut | |
| 700 | 1 | |a Perno, C F |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, M M |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccherini-Silberstein, F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology |d 1997 |g 168(2023) vom: 07. Nov., Seite 105551 |w (DE-627)NLM097223964 |x 1873-5967 |7 nnns |
| 773 | 1 | 8 | |g volume:168 |g year:2023 |g day:07 |g month:11 |g pages:105551 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcv.2023.105551 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 168 |j 2023 |b 07 |c 11 |h 105551 | ||